Viking Therapeutics Inc (VKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.73B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viking Therapeutics Inc (VKTX) Stock Forecast
Analysts expect Viking Therapeutics (VKTX) to earn -$5.31 per share in the fiscal year ending Dec 31, 2026. Of 21 analysts, 19 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 10 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 21 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 23.8% |
| Buy | 14 | 66.7% |
| Hold | 2 | 9.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 21
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$5.31
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$5.21
- EPS consensus
- Next report
- Feb 9, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$5.31 | -$5.66 to -$4.58 | 18 |
| Dec 31, 2027 | -$5.21 | -$7.29 to -$3.79 | 18 |
Quarterly Estimates
The EPS consensus falls from -$1.32 for the quarter ending Dec 31, 2026 to -$1.36 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.32 | -$1.60 to -$0.79 | 22 |
| Mar 31, 2027 | -$1.36 | -$1.71 to -$1.12 | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 19 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 10 |
| Fiscal year ending Dec 31, 2027 | 5 | 6 |
| Quarter ending Mar 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.63.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.31 | -$4.59 | -$4.61 | -$4.61 | -$4.63 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.21 | -$4.34 | -$4.40 | -$4.32 | -$4.33 | N/A |
| Quarter ending Mar 31, 2027 | -$1.36 | -$1.04 | -$1.05 | -$1.05 | -$1.05 | N/A |
Frequently Asked Questions About VKTX
What is the VKTX stock forecast?
Consensus analyst estimates put Viking Therapeutics's EPS at -$5.31 for the fiscal year ending Dec 31, 2026. The consensus rating from 21 analysts is Buy.
How do analysts rate VKTX stock?
Of 21 analysts covering Viking Therapeutics, 5 rate it Strong Buy, 14 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VKTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.31, with estimates from -$5.66 to -$4.58 from 18 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.21, with estimates from -$7.29 to -$3.79 from 18 analysts.
How many analysts cover VKTX?
21 analysts rate Viking Therapeutics stock, and 18 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VKTX pages: Overview, Earnings, Forecast, Financials, Competitors